The content provided in this video is for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell any securities. All views expressed are those of InsightfulValue and are based on publicly available information believed to be reliable, but no guarantee is made as to its accuracy or completeness. Always conduct your own research or consult a licensed financial advisor before making any investment decisions. Investing in the stock market involves risks, including the loss of principal.
Please be aware that the stock prices displayed on this website represent a curated selection of data. On desktop devices, you will see a wider range of stock prices, while on mobile devices, we provide a more streamlined view for better user experience and readability.
Our focus is on assessing a company's overall value and performance, rather than analyzing price fluctuations, even if we do watch prices in order to find companies trading below their intrinsic value. For more detailed charting and comprehensive market analysis, we recommend consulting a professional financial service or utilizing advanced charting tools.
We strive to provide accurate and timely information, but we encourage you to verify any financial data before making investment decisions.
Infographic
Overview
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana. It was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist, and is one of the largest pharmaceutical companies in the world. The company's primary focus is on the development and production of prescription medications in various therapeutic areas, including neuroscience, oncology, immunology, and diabetes. Some of its most well-known products include the antidepressant Prozac, the erectile dysfunction drug Cialis, and the insulin Humalog. Eli Lilly and Company also has a strong global presence, with operations in over 125 countries and sales in more than 120 countries. The company has a long history of innovation and has been responsible for groundbreaking medical discoveries, such as the first commercially available insulin in 1923. In addition to its pharmaceutical business, Eli Lilly and Company also has a strong commitment to corporate responsibility and sustainability. The company has implemented various initiatives to reduce its environmental impact, improve access to healthcare, and support local communities. Eli Lilly and Company employs over 35,000 people worldwide and has been consistently ranked as one of the top places to work by various publications. The company continues to invest in research and development to bring new and innovative treatments to patients around the world.
How to explain to a 10 year old kid about the company?
π Want to read more about Eli Lilly and Company?
AI presents both opportunities and challenges for Eli Lilly and Company. 1. Substitution: AI technologies, particularly in drug discovery and development, could lead to new competitors emerging that utilize advanced algorithms to identify and develop alternatives to Eli Lillyβs products. These competitors may be able to bring drugs to market more efficiently and with potentially lower costs, which could threaten Eli Lillyβs market share in specific therapeutic areas. 2. Disintermediation: AI can enable new approaches to healthcare delivery and patient management, potentially reducing the need for traditional pharmaceutical distribution channels. For instance, direct-to-consumer models powered by AI advancements in diagnostics or personalized medicine may diminish the role of established pharmaceutical companies. This could lead to a reevaluation of Eli Lillyβs distribution strategies and partnerships. 3. Margin Pressure: As AI drives efficiencies in drug development and production processes, competitors utilizing these technologies may be able to produce drugs at lower costs. This could result in price pressures within the pharmaceutical industry, impacting Eli Lillyβs profit margins. Furthermore, if AI leads to the rapid introduction of generic versions of brand-name drugs, Eli Lillyβs revenue streams could be affected. Overall, while AI poses some risks regarding substitution, disintermediation, and margin pressure, it also offers Eli Lilly the potential to enhance its own research capabilities, streamline operations, and improve patient outcomes. The company will need to strategically integrate AI technologies to mitigate these threats and leverage the advantages they offer.
Sensitivity to interest rates
The sensitivity of Eli Lilly and Companyβs earnings, cash flow, and valuation to changes in interest rates can be attributed to several factors: 1. Earnings Sensitivity: Eli Lillyβs earnings can be impacted by interest rates through the cost of debt. If interest rates rise, the companyβs borrowing costs may increase. This can affect net income, especially if the company relies on debt for expansion or operational funding. Conversely, lower interest rates can enhance profitability by reducing interest expenses. 2. Cash Flow Sensitivity: Interest rates can influence cash flow, particularly in terms of financing activities. As rates rise, cash outflows for interest payments may increase, affecting free cash flow. Additionally, if clients or partners are sensitive to interest ratesβlike healthcare providers that may face budget constraintsβthis could impact the companyβs cash flow. 3. Valuation Sensitivity: The valuation of Eli Lilly is often assessed using discounted cash flow (DCF) models. Higher interest rates increase the discount rate applied to future cash flows, which can lower the present value of those cash flows and potentially decrease the companyβs stock price. Lower rates would have the opposite effect, making the companyβs future cash flows appear more valuable. In summary, while Eli Lilly is fundamentally a pharmaceutical company with its own unique cash flow drivers, it is still susceptible to shifts in interest rates, particularly through financing costs and valuation implications.
Resilience to the future changes
π Want to read more about Eli Lilly and Company?
π InsightfulValue is a platform for public company analysis.
π We provide a database of public companies, with a focus on value investing principles.
π We carefully select every company in our database. With only 1860 listed, there's a reason for that.
π The reason is simple β we only select the best-performing public companies, true champions. And we know exactly what we mean by "champion."
π For us, a champion is a company with strong finances, a history of impressive dividends, great management, and standout products or services. We mean it.
π For each company, we have 663 questions and answers covering every aspect of their market position and operations. Everything.
π ... plus additional 164 Q&A about the industry each company operates in.
InsightfulValue is an independent platform dedicated to value investing research. The information provided on this website is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. We are not financial advisors, investment consultants, or licensed consultants. Our analyses, insights, and criteria are based on principles learned from renowned value investors such as Benjamin Graham, Warren Buffett, and Charlie Munger, but they should not be considered personalized investment recommendations. Investing in financial markets carries risks, and past performance is not indicative of future results. Users of this website should conduct their own due diligence and consult with a qualified professional before making any financial or investment decisions. InsightfulValue assumes no liability for any financial losses or decisions made based on the information provided on this site. By using this website, you acknowledge and accept that all investments involve risk and that InsightfulValue does not guarantee any financial outcomes.